PNC-27

PNC-27 Molecular Structure & Chemical Properties

PNC-27 represents a unique approach in preclinical cancer research, designed to selectively target membrane-expressed HDM-2 protein in cancer cell membranes. Developed in 2000 at SUNY Downstate Medical Center, this chimeric peptide combines a p53-derived HDM-2 binding domain with a cell-penetrating peptide sequence, creating a 32-amino acid construct that has been investigated across multiple cancer cell line models. Unlike conventional cytotoxic agents that indiscriminately affect both normal and transformed cells, PNC-27’s mechanism specifically targets a structural feature that distinguishes cancer cells from healthy tissue – the presence of HDM-2 protein in plasma membranes. This peptide has been the subject of extensive in vitro and in vivo animal research examining its potential as a selective anti-cancer agent, though critical translational gaps remain.

Note: PNC-27 is not currently indexed in PubChem. Structure information is based on published sequence data.

Technical Specifications

The peptide structure consists of two functional domains: the N-terminal p53-derived sequence (residues 12-26) that binds HDM-2, and the C-terminal membrane residency peptide derived from the Antennapedia homeodomain protein, which enables cellular penetration and membrane interaction.

PNC-27 Mechanism of Action

PNC-27 operates through a highly selective mechanism that distinguishes it from conventional cytotoxic agents. The peptide’s anti-cancer activity depends fundamentally on the aberrant expression of HDM-2 protein in cancer cell plasma membranes – a characteristic present in many transformed cell lines but absent in normal, untransformed cells. This membrane localization of HDM-2 serves as the molecular target that enables selective cancer cell killing.

Primary Cellular Pathways

HDM-2 Membrane Binding – Selective Target Recognition

Research has demonstrated that PNC-27 binds specifically to HDM-2 protein expressed in cancer cell membranes through its p53-derived binding domain (residues 12-26). Structural studies using nuclear magnetic resonance and conformational energy calculations show that PNC-27 adopts a conformation similar to native p53 when binding to HDM-2’s p53-binding pocket. Key findings include:

• Selective binding to membrane-associated HDM-2 in cancer cells
• Formation of 1:1 PNC-27-HDM-2 complexes at the membrane surface
• Co-localization confirmed through immunofluorescence microscopy
• No binding observed in normal cells lacking membrane HDM-2 expression

Studies using transfection experiments demonstrated that untransformed cells expressing HDM-2 on their membranes became susceptible to PNC-27, while cells expressing HDM-2 lacking the p53-binding domain remained resistant, confirming the specific binding mechanism.

Transmembrane Pore Formation – Membranolysis Mechanism

Following HDM-2 binding, PNC-27 induces the formation of transmembrane pores in cancer cell membranes, leading to rapid cell lysis and necrosis. Electron microscopy studies have revealed:

• Ring-shaped pore structures containing PNC-27-HDM-2 complexes in approximately 1:1 ratios
• Pore formation within 15-30 minutes of peptide exposure
• Pores lined by multiple PNC-27-HDM-2 complexes
• Membrane residency peptide domain extending through the lipid bilayer

The pores disrupt osmotic balance, causing rapid influx of extracellular fluid and extrusion of intracellular contents, including lactate dehydrogenase, which serves as a marker for necrotic cell death.

Necrosis Induction – Distinct from Apoptosis

Unlike many anti-cancer agents that trigger programmed cell death through apoptotic pathways, PNC-27 induces necrotic cell death characterized by:

• Rapid lactate dehydrogenase release within 4 hours
• Absence of caspase activation (caspase-3 and caspase-7 remain at baseline)
• No DNA laddering or other apoptotic hallmarks
• Cell membrane rupture and cytoplasmic swelling
• Mitochondrial disruption observed in treated cells

This necrotic mechanism enables PNC-27 to kill cancer cells that lack functional p53 or contain p53 deletions/mutations, potentially addressing a limitation of apoptosis-inducing agents that require intact p53 signaling.

Mitochondrial Interaction – Secondary Target

Recent research has identified an additional mechanism involving mitochondrial membrane disruption:

• PNC-27 penetrates cancer cells and localizes to mitochondrial membranes
• Binding to mitochondrial membranes causes organelle swelling and disruption
• This secondary mechanism may contribute to rapid cell death
• Mitochondrial effects observed within 30 minutes of treatment

The dual targeting of both plasma and mitochondrial membranes may enhance the rapid cytotoxic effects observed in preclinical models.

PNC-27 Research Applications & Key Findings

Solid Tissue Cancer Research

Pancreatic Cancer Models

PNC-27 has been extensively studied in pancreatic cancer cell lines, with research showing selective cytotoxicity in multiple models:

• Cytotoxic effects demonstrated in MIA-PaCa-2 human pancreatic adenocarcinoma cells
• Dose-dependent cell killing with nearly 100% cell death at 300 mcg/ml within 90 minutes
• In vivo studies in nude mice showed tumor growth inhibition following peptide administration
• PNC-28 (a related peptide) demonstrated tumor size reduction when injected directly into pancreatic tumors in animal models

Research published in 2006 showed that PNC-28 blocked pancreatic cancer growth in vivo when administered either directly to tumors or from distant sites.

Breast Cancer Research

Studies in human breast cancer cell lines revealed selective cytotoxicity across different p53 mutation statuses:

• Effective against MDA-MB-468 cells (mutant p53)
• Cytotoxic to MCF-7 cells (wild-type p53 overexpression)
• Active against MDA-MB-157 cells (p53-null)
• Selectivity confirmed by lack of toxicity to normal human fibroblasts

These findings suggested that PNC-27’s mechanism operates independently of cellular p53 status, potentially addressing cancers with p53 dysfunction.

Leukemia and Hematological Cancer Research

Acute Myeloid Leukemia Cell Lines

Research examined PNC-27 effects on non-solid tissue cancers, including multiple AML cell lines:

• U937 cells showed high sensitivity with IC50 of 4.7 micromolar after 4 hours
• OCI-AML3 cells demonstrated IC50 of 83.9 micromolar
• HL60 cells showed IC50 of 91.1 micromolar
• K562 chronic myeloid leukemia cells (p53-deleted) exhibited nearly 100% cell killing

Flow cytometry confirmed HDM-2 membrane expression in all sensitive leukemia cell lines, while normal rat mononuclear cells showed no cytotoxicity even at high peptide concentrations.

Ovarian Cancer Research

Preclinical studies investigated PNC-27 in epithelial ovarian cancer models:

• High membrane HDM-2 expression confirmed in ovarian cancer cell lines
• Selective cytotoxicity demonstrated in multiple ovarian cancer cell lines
• Ex vivo studies with primary human ovarian cancer tissue showed peptide activity
• Dose-dependent effects with preferential killing of cancer cells versus normal cells

Research suggested potential applicability to gynecological malignancies based on membrane HDM-2 expression patterns.

Additional Cancer Cell Line Research

PNC-27 has been investigated across a diverse range of cancer types:

• Melanoma (A2058 cells) – selective cytotoxicity demonstrated
• Colon adenocarcinoma – cell death in human metastatic cell lines
• Cervical carcinoma – cytotoxic effects in HeLa and other cervical cancer cells
• Osteosarcoma – activity demonstrated in bone cancer models
• Brain cancer – effects observed in transformed rat brain capillary endothelial cells

PNC-27 Pharmacokinetics & Metabolism

Absorption & Distribution

Limited pharmacokinetic data exists for PNC-27, as most research has focused on mechanism and efficacy rather than ADME properties. Based on its peptide structure and available research:

• Peptide-based structure suggests rapid enzymatic degradation in physiological conditions
• Cell-penetrating peptide domain enables cellular uptake
• Distribution to tumor sites demonstrated in animal models
• Subcutaneous administration showed bioavailability in preclinical studies

The membrane residency peptide component, derived from Antennapedia, facilitates cellular penetration and membrane association, distinguishing PNC-27 from non-penetrating peptides.

Metabolism & Elimination

As a 32-amino acid peptide, PNC-27 likely undergoes rapid metabolism through peptidase-mediated degradation:

• Plasma half-life expected to be short (minutes to hours) typical of unmodified peptides
• Enzymatic cleavage by serum and tissue peptidases represents primary metabolic pathway
• Metabolic products likely include amino acid fragments
• Studies requiring daily or twice-daily dosing in animal models suggest rapid clearance

The paradox of rapid peptide degradation versus prolonged biological effects observed in some studies has not been fully explained. Possibilities include sustained signaling after initial membrane interaction or tissue retention of the peptide.

Excretion Pathways

Specific excretion data for PNC-27 is limited, but peptide pharmacokinetics generally indicate:

• Renal filtration and excretion of peptide fragments
• Hepatic metabolism may contribute to clearance
• Complete clearance likely occurs within hours based on peptide size
• No accumulation anticipated based on structural characteristics

The lack of comprehensive pharmacokinetic studies represents a significant gap, as optimization of dosing regimens would require detailed ADME characterization.

PNC-27 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse PNC-27 concentrations depending on model system and experimental design:

• In vitro cell culture: 25-300 mcg/ml (approximately 6-75 micromolar) for 4-48 hours
• Pancreatic cancer cells: 100-300 mcg/ml achieved nearly complete cell killing in 90 minutes
• Leukemia cell lines: 25-100 micromolar range with variable sensitivity by cell type
• Animal models: Dosing protocols varied; direct tumor injection and systemic administration both studied
• Daily administration: Multiple studies required daily dosing, suggesting short duration of action

Important: These are experimental concentrations and doses used in cell culture and animal studies and cannot be extrapolated to other species due to profound differences in metabolism, peptide stability, pharmacokinetics, immune responses, and tissue distribution. Species-specific factors fundamentally influence both efficacy and safety profiles. Furthermore, optimal human dosing has never been established.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical models:

• Intraperitoneal injection – Common route in rodent cancer models; enables systemic delivery
• Direct intratumoral injection – Used in some solid tumor studies; highest local concentration
• Subcutaneous injection – Investigated for systemic peptide delivery
• Intravenous injection – Limited studies; rapid systemic distribution
• Nebulized solution – Studied for potential pulmonary delivery (associated with FDA contamination warning)

The FDA has specifically warned against human use of PNC-27 in any formulation, including nebulized solutions, intravenous preparations, and suppositories.

Common Model Organisms and Cell Lines

PNC-27 research has utilized diverse experimental systems:

• Cell culture models – Human cancer cell lines: MIA-PaCa-2, MCF-7, MDA-MB-468, U937, K562, A2058, HeLa, and numerous others
• Mouse models – Nude mice bearing human tumor xenografts; most common in vivo system
• Normal cell controls – Human fibroblasts, rat pancreatic acinar cells, normal lymphocytes
• Primary cells – Ex vivo studies with primary human ovarian and endometrial cancer tissue

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite two decades of preclinical investigation, PNC-27 faces substantial translational barriers that severely limit any potential clinical application.

Absence of Human Clinical Data

The most significant limitation is the complete lack of human clinical trial data:

• No Phase I safety studies have been published or registered in clinical trial databases
• No Phase II efficacy studies exist
• No Phase III randomized controlled trials
• Human pharmacokinetics, safety, tolerability, and efficacy completely unknown
• Optimal human dosing cannot be determined from animal data
• Drug-drug interactions uncharacterized
• Long-term safety profile in humans nonexistent

Mechanistic Understanding Gaps

Fundamental aspects of PNC-27’s mechanism remain incompletely characterized:

• Molecular basis for HDM-2 membrane localization in cancer cells poorly understood
• Why normal cells do not express membrane HDM-2 remains unclear
• Structural requirements for pore formation need further elucidation
• Relationship between membrane pore formation and mitochondrial disruption undefined
• Whether peptide modifications could improve stability or selectivity unexplored

Manufacturing and Quality Concerns

The FDA’s 2017 contamination warning highlighted serious manufacturing issues:

• Bacterial contamination (Variovorax paradoxus, Ralstonia insidiosa) detected in marketed products
• Lack of current good manufacturing practice compliance
• Quality control failures in products marketed to cancer patients
• Criminal prosecution of individuals manufacturing and distributing unapproved PNC-27 products

Long-Term Safety Considerations

Multiple safety questions remain unaddressed:

• Chronic exposure effects completely unstudied in any species
• Potential for off-target effects unknown
• Immunogenicity and antibody development possible with repeated dosing
• Theoretical concerns about normal tissue damage if low-level HDM-2 membrane expression exists
• Interaction with conventional cancer therapies unexplored
• Effects on hematopoiesis and immune function uncharacterized

Regulatory & Legal Status

FDA Position

PNC-27 has not received FDA approval and faces explicit regulatory warnings:

• Not approved for any indication in humans or animals
• Classified as an unapproved drug under Federal Food, Drug, and Cosmetic Act
• FDA issued warning in January 2017 against purchasing or using PNC-27 products
• Contamination of marketed products detected (bacterial contamination)
• Federal prosecution of individuals manufacturing and distributing PNC-27 occurred in 2021
• Marketing PNC-27 for human use violates federal law

The FDA explicitly stated: “FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer.”

WADA and Athletic Use

Unlike some research peptides, PNC-27 has not been specifically listed on WADA’s prohibited list. However:

• As an unapproved substance, it would fall under WADA Section S0 (Non-Approved Substances)
• No legitimate therapeutic use recognized by any regulatory authority
• Use in competitive athletics would likely be considered a violation
• No Therapeutic Use Exemptions available for unapproved substances

Legal Consequences

Federal enforcement actions have been taken against PNC-27 distribution:

• Criminal conviction in 2021 of individual manufacturing and distributing PNC-27
• Charges included conspiracy to commit fraud and distribution of misbranded drugs
• Five-year debarment from importing drugs into the United States
• Millions of dollars in payments received for illegal products

Research Classification: PNC-27 is available only for legitimate laboratory research use conducted under appropriate institutional oversight. It is not intended for human consumption, medical use, veterinary applications, or athletic performance enhancement. All research must comply with institutional review board requirements and applicable regulations.

References

1. Sarafraz-Yazdi, E., Mumin, S., Cheung, D., Fridman, D., Lin, B., Wong, L., Rosal, R., Rudolph, R., Frenkel, M., Thadi, A., Morano, W.F., Bowne, W.B., Pincus, M.R., & Michl, J. (2022). PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines, 10(5), 945. PubMed
   
2. Sarafraz-Yazdi, E., Bowne, W.B., Adler, V., Sookraj, K.A., Malhotra, V., Shanzer, M., Pincus, M.R., & Michl, J. (2010). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences, 107(5), 1918-1923. PubMed
   
3. Thadi, A., Lewis, L., Goldstein, E., Aggarwal, A., Khalili, M., Steele, L., Polyak, B., Seydafkan, S., Bluth, M.H., Ward, K.A., Styler, M., Campbell, P.M., Pincus, M.R., & Bowne, W.B. (2020). Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. Anticancer Research, 40(9), 4857-4867. PubMed
   
4. Davitt, K., Babcock, B.D., Fenelus, M., Poon, C.K., Sarkar, A., Trivigno, V., Zolkind, P.A., Matthew, S.M., Grin’kina, N., Orynbayeva, Z., Shaikh, M.F., Adler, V., Michl, J., Sarafraz-Yazdi, E., Pincus, M.R., & Bowne, W.B. (2014). The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science, 44(3), 241-248. PubMed
   
5. Krzesaj, P., Adler, V., Feinman, R.D., Miller, A., Silberstein, M., Sarafraz-Yazdi, E., & Pincus, M.R. (2024). Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Annals of Clinical and Laboratory Science, 54(3), 258-266. PubMed
   
6. Michl, J., Scharf, B., Schmidt, A., Huynh, C., Hannan, R., von Gizycki, H., Friedman, F.K., Brandt-Rauf, P., Fine, R.L., & Pincus, M.R. (2006). PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer, 119(7), 1577-1585. PubMed
   
7. Bowne, W.B., Sookraj, K.A., Vishnevetsky, M., Adler, V., Sarafraz-Yazdi, E., Lou, S., Koenke, J., Shteyler, V., Ikram, K., Harding, M., Bluth, M.H., Ng, M., Brandt-Rauf, P.W., Hannan, R., Bradu, S., Zenilman, M.E., Michl, J., & Pincus, M.R. (2008). The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Annals of Surgical Oncology, 15(12), 3588-3600. PubMed
   
8. Kanovsky, M., Raffo, A., Drew, L., Rosal, R., Do, T., Friedman, F.K., Rubinfeld, B., Visvanathan, J., Hung, D.T., Brandt-Rauf, P.W., Zenilman, M., Michl, J., & Pincus, M.R. (2001). Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proceedings of the National Academy of Sciences, 98(22), 12438-12443. PubMed
   
9. Do, T., Ho, F., Hahn, J., Weerakkody, D., Dejneka, N., Raffo, A.J., Michl, J., Pincus, M.R., & Brandt-Rauf, P.W. (2003). p53 Peptides bind to HDM-2 in solution and induce selective cytotoxicity to cancer cells. Oncogene, 22(13), 1984-1993. PubMed
   
10. Thadi, A., Gleeson, E.M., Khalili, M., Shaikh, M.F., Goldstein, E., Morano, W.F., Daniels, L.M., Grandhi, N., Glatthorn, H., Richard, S.D., Campbell, P.M., Sarafraz-Yazdi, E., Pincus, M.R., & Bowne, W.B. (2020). Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes. Annals of Clinical and Laboratory Science, 50(5), 611-624. PubMed
    
11. Sarafraz-Yazdi, E., Gorelick, C., Wagreich, A., Salame, G., Angert, M., Gartman, C.H., Gupta, V., Bowne, W.B., Lee, Y.C., Abulafia, O., Pincus, M.R., & Michl, J. (2015). Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer. Journal of Cancer Therapy, 6, 1188-1198.
12. Wang, H., Chen, Y., Lu, X.A., Liu, G., Fu, Y., & Luo, Y. (2020). Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia, 34(1), 75-86. PubMed
    
13. Pincus, M.R., Silberstein, M., Zohar, N., Sarafraz-Yazdi, E., & Bowne, W.B. (2024). Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines, 12(6), 1144. PubMed
    
14. Marqus, S., Pirogova, E., & Piva, T.J. (2017). Evaluation of the use of therapeutic peptides for cancer treatment. Journal of Biomedical Science, 24(1), 21. PubMed
    
15. U.S. Food and Drug Administration. (2017). FDA warns cancer patients not to use PNC-27 products for treatment. FDA Safety Communication. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-cancer-patients-not-use-pnc-27-products-treatment

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. PNC-27 is intended for laboratory research use only.